Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Neuroscience Right
  3. Emgality (galcanezumab-gnlm) injection Right
  4. What does the suffix "gnlm" mean after galcanezumab in the Emgality® (galcanezumab-gnlm) package insert?
Search Emgality (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What does the suffix "gnlm" mean after galcanezumab in the Emgality® (galcanezumab-gnlm) package insert?

The suffix "gnlm" added to galcanezumab does not have any clinical meaning.

US_cFAQ_GLC011_GENERIC_NAME_SUFFIX
US_cFAQ_GLC011_GENERIC_NAME_SUFFIX
en-US

Food and Drug Administration Guidance

The suffix assigned to galcanezumab, -gnlm, is a Food and Drug Administration (FDA)-designated suffix applicable in the United States only. The FDA issued guidance in 2017 regarding the addition of 4-letter suffixes to the end of the core name of newly approved biologics.1 

The suffixes

  • are unique to each core name
  • have no meaning
  • consist of 4 lower-case letters, of which at least 3 are distinct
  • are nonproprietary
  • are attached to the core name via hyphen, and
  • are free from usage-restricting legal barriers.1

According to the FDA, the suffix can

  • serve as a key element to identify specific products in spontaneous adverse event reporting
  • help to avoid the inaccurate perception of safety and efficacy based on licensure pathway
  • minimize inadvertent substitutions that are not interchangeable, and
  • reinforce accurate product identification in prescribing, billing, and claims records used for active pharmacovigilance.1

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

Reference

1US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Nonproprietary naming of biological products: guidance for industry. January 2017. Accessed November 10, 2021. https://www.fda.gov/downloads/drugs/guidances/ucm459987.pdf

Date of Last Review: November 10, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly